Helix BioPharma Announces Financial Results

Helix BioPharma (TSE:HPB) has announced its financial results for the year ended July 31.
According to the press release:

The Company initiated three clinical sites for its U.S. Phase I study of L-DOS47 in combination with pemetrexed/carboplatin in patients with Stage 4 recurrent or metastatic non-squamous non-small-cell lung cancer (“NSCLC”). Two patients have been dosed, to date. The clinical sites initiated include:
The University of Texas, M.D. Anderson Cancer Centre; Penn State Milton S. Hershey Medical Center; and University Hospitals Case Medical Center
[…] The Company Phase I/II clinical study in Poland continues to move forward. The Central Ethics Committee overseeing the clinical study in Poland approved an additional four cohort dose levels which permits the Company to dose escalate patients up to Cohort 16. Patients in Cohort 13 are currently being dosed.

Click here to read the full press release.